Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (4): 579-584    DOI: 10.12892/ejgo4179.2018
Original Research Previous articles | Next articles
Clinical effects of comprehensive treatments for FIGO Stage IIB adenocarcinoma/adenosquamous carcinoma of the cervix
Ying Yao1, †, Le Chen1, †, Huiying Yu2, Hongyun Xiang3, Jing Yao4, Jie Tang1, *()
1 Department of Gynecologic Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
2 Department of Obstetrics and Gynecology, the First Hospital of Chenzhou, the affiliated Hospital of University of South China, Chenzhou, China
3 Department of Obstetrics and Gynecology, Jingzhou People’s Hospital, the affiliated Hospital of University of South China, Jingzhou, China
4 Department of Obstetrics and Gynecology, the First Hospital of Loudi, the affiliated Hospital of University of South China, Loudi, China
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
To evaluate the clinical effects of comprehensive treatments for the FIGO Stage IIB adenocarcinoma (AC) / adenosquamous carcinoma (ASC) of cervix of patients from four institutions between 2000 and 2009 with Stage IIB AC/ASC of cervix that were included and divided into two groups. Both groups received initial cisplatin-based neoadjuvant chemotherapy (NACT) treatment. Radical surgery (RS, n=70) group subsequently underwent surgery followed by adjuvant chemo-radiotherapy, while the radiotherapy (RT, n=70) group received the standard concurrent chemo-radiotherapy alone. Differences in outcomes were compared. Multivariate analysis was used. The overall survival (OS) was 74.3% vs. 52.9% (p = 0.002) and progression free survival (PFS) rates were 64.3% vs. 44.3 %( p = 0.007) in each group. Complications in the RS group were acceptable. Presence of lymph node metastasis was a significant factor in determining OS. The authors conclude that NACT combined with RS followed by adjuvant chemo-radiotherapy is a promising treatment option for Stage IIB AC/ASC of the cervix.
Key words:  Cervical cancer      Concurrent chemo-radiation      FIGO stage IIB      Adenocarcinoma/adenosquamous carcinoma      Radical surgery      Prognostic factors     
Published:  10 August 2018     
*Corresponding Author(s):  JIE TANG     E-mail:  tanjie_hospital@126.com
About author:  † Contributed equally.

Cite this article: 

Ying Yao, Le Chen, Huiying Yu, Hongyun Xiang, Jing Yao, Jie Tang. Clinical effects of comprehensive treatments for FIGO Stage IIB adenocarcinoma/adenosquamous carcinoma of the cervix. European Journal of Gynaecological Oncology, 2018, 39(4): 579-584.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4179.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I4/579

[1] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[2] Liman Yang, Jing Jin, Juhong Liu. Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 508-512.
[3] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[4] Fengmei Wang , Huachun Luo , Huihua Cheng, Huijuan Huang , Zhichao Fu. Is 3D printing-gided three-dimensional brachytherapy suitable for cervical cancer: from one single research institute?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 591-597.
[5] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta. Successful treatment of uterine cervical carcinoma with extensive vaginal lesions using laparoscopic surgery: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 629-633.
[6] Hikari Unno, Seiji Mabuchi, Isao Arai, Tomoko Wakasa, Seiichi Yamamasu. Development of lymphangiosarcoma after pelvic radiation therapy for uterine cervical cancer: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 326-331.
[7] L. Xu, H. Cai, N. Zhu, Bo Zheng. Interleukin-22 derived from cervical cancer-associated fibroblasts accelerates senescence of normal fibroblasts and promotes expression of tumorigenesis-related factors in HeLa cells[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 192-199.
[8] Hong Yan, Chunhua Zhang, Tingting Liu, Jianzhong Liu. Mifepristone regulates the multidrug resistance via miR-758/MEPE of Hela cell lines[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 214-220.
[9] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[10] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
[11] B. Bárány, R. Póka. Nutritional assessment among patients with cervical cancer and controls[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 23-29.
[12] D. Kim, Y. Ki, W. Kim, D. Park, D. Suh, K. Kim, J. Lee, H. Jeon, J. Nam. Positive pelvic lymph node on [18F]-FDG PET is a prognostic factor in early-stage high-risk cervical cancer treated by radical hysterectomy and adjuvant chemoradiotherapy[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 42-47.
[13] H. Imafuku, Y. Ebina, K. Suzuki, S. Wakahashi, Y. Miyahara, K. Yoshida, H. Yamada. Definitive radiotherapy in elderly patients and patients with locally advanced cervical cancer with complications[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 60-64.
[14] Y. Murata, Y. Miyahara, K. Suzuki, S. Wakahashi, T. Sudo, S. Nagao, S. Yamaguchi, Y. Ebina, H. Yamada. Leukocytosis and thrombocytosis as prognostic factors for women with uterine cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 93-97.
[15] N. Habib, T. Dennis, G. Centini, L. Bresson, F. Narducci, E. Leblanc. Glassy cell carcinoma: is surgical treatment with preservation of the uterus a therapeutic option?[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 121-125.
No Suggested Reading articles found!